Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 87
Filtrar
1.
Br J Dermatol ; 180(4): 715-729, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-30183065

RESUMEN

BACKGROUND: Topical photodynamic therapy (PDT) is widely used to treat superficial nonmelanoma skin cancer and dysplasia, and is generally well tolerated. However, as with all treatments, adverse effects may occur and awareness may facilitate approaches to prevention and management. OBJECTIVES: To review the available evidence relating to the adverse effects of topical PDT, to help inform recommendations in updated clinical guidelines produced by the British Association of Dermatologists and British Photodermatology Group, and the efficacy of preventative and therapeutic approaches. METHODS: This review summarizes the published evidence related to the adverse effects of topical PDT and attempts to interpret this evidence in the context of patient risk and management. RESULTS: Pain and discomfort during PDT are acute adverse effects, which can be minimized through the use of modified and low-irradiance PDT regimens and do not therefore usually limit successful treatment delivery. Other adverse effects include the risk of contact allergy to photosensitizer prodrugs, although this is rare but should be kept in mind, particularly for patients who have received multiple PDT treatments to larger areas. There are no other significant documented longer-term risks and, to date, no evidence of cumulative toxicity or photocarcinogenic risk. CONCLUSIONS: Topical PDT is usually well tolerated, reinforcing the utility of this important therapeutic option in dermatology practice. The main acute adverse effect of pain can typically be minimized through preventative approaches of modified PDT regimens. Other adverse effects are uncommon and generally do not limit treatment delivery.


Asunto(s)
Dolor Agudo/terapia , Manejo del Dolor/métodos , Fotoquimioterapia/efectos adversos , Fármacos Fotosensibilizantes/efectos adversos , Neoplasias Cutáneas/tratamiento farmacológico , Dolor Agudo/etiología , Administración Cutánea , Consenso , Femenino , Humanos , Persona de Mediana Edad , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/administración & dosificación
3.
Br J Dermatol ; 179(6): 1277-1296, 2018 12.
Artículo en Inglés | MEDLINE | ID: mdl-29889302

RESUMEN

BACKGROUND: Topical photodynamic therapy (PDT) is an established treatment option for low-risk basal cell carcinoma (BCC). OBJECTIVES: To compare efficacy, cosmesis and tolerability of PDT for BCC with alternative treatments. METHODS: MEDLINE, PubMed, Embase and CENTRAL databases were searched from inception until 1 September 2017. Included studies were randomized controlled trials (RCTs) of PDT for nodular (n) and superficial (s) BCC reporting at least one of the following outcomes: clearance at 3 months and sustained at 1 or 5 years; recurrence at ≥ 1 year; cosmesis; adverse events; tolerability. RESULTS: From 2331 search results, 15 RCTs (2327 patients; 3509 BCCs) were included. PDT efficacy (5-year sustained clearance) was high but inferior to excisional surgery [nBCC pooled risk ratio (RR) 0·76; 95% confidence interval (CI) 0·63-0·91], and without re-treatment of partially responding lesions, was modestly inferior to imiquimod (sBCC: RR 0·81; 95% CI 0·70-0·95) and similar to fluorouracil (sBCC: RR 0·88; 95% CI 0·75-1·04). Five-year sustained clearance was inferior with conventional vs. fractionated PDT (sBCC: RR 0·76; 95% CI 0·68-0·84). PDT cosmesis was superior to surgery (sBCC: RR 1·68, 95% CI 1·32-2·14; nBCC: RR 1·82, 95% CI 1·19-2·80) and cryosurgery (BCC: RR 3·73, 95% CI 1·96-7·07), and without re-treatment of partially responding lesions was similar to imiquimod (sBCC: RR 1·01, 95% CI 0·85-1·19) and fluorouracil (sBCC: RR 1·04, 95% CI 0·88-1·24). Peak pain was higher but of shorter duration with PDT than topical treatments. Serious adverse reactions were rarer with PDT than imiquimod (sBCC: RR 0·05, 95% CI 0·00-0·84) and fluorouracil (sBCC: RR 0·11, 95% CI 0·01-2·04). Combination PDT regimens demonstrated reduced recurrence and improved cosmesis; however, results from these small studies were often nonsignificant. CONCLUSIONS: PDT is an effective treatment for low-risk BCC, with excellent cosmesis and safety. Imiquimod has higher efficacy than single-cycle PDT but more adverse effects. Highest efficacy is with excisional surgery. Fractionated and combination PDT options warrant further study.


Asunto(s)
Antineoplásicos/administración & dosificación , Carcinoma Basocelular/terapia , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/administración & dosificación , Neoplasias Cutáneas/terapia , Administración Tópica , Antineoplásicos/efectos adversos , Carcinoma Basocelular/patología , Criocirugía/efectos adversos , Criocirugía/métodos , Fraccionamiento de la Dosis de Radiación , Estética , Humanos , Imiquimod/administración & dosificación , Imiquimod/efectos adversos , Recurrencia Local de Neoplasia/epidemiología , Recurrencia Local de Neoplasia/prevención & control , Dolor/diagnóstico , Dolor/etiología , Dimensión del Dolor , Seguridad del Paciente , Fotoquimioterapia/efectos adversos , Fármacos Fotosensibilizantes/efectos adversos , Ensayos Clínicos Controlados Aleatorios como Asunto , Neoplasias Cutáneas/patología , Resultado del Tratamiento
4.
Dermatology ; 221(4): 326-30, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20881360

RESUMEN

BACKGROUND: Aquagenic wrinkling of the palms (AWP) is a rare condition characterised by the development of oedema and excessive wrinkling of the palms following exposure to water. It has frequently been associated with cystic fibrosis (CF). Early reports of AWP have only been case reports or small case series; there has only been one reported prevalence study of AWP in a CF population. OBJECTIVE: To determine the incidence and characteristics of AWP in the adult CF population in Northern Ireland. METHODS: 105 CF patients were interviewed. The patients were asked whether they noticed excess wrinkling of the hands when exposed to water. If they answered 'yes', further questions were asked regarding clinical characteristics. The atopic status, CF genotype and drug history were recorded for each patient. Formal testing of 7 patients was carried out. RESULTS: Out of the 105 patients who were interviewed, 43 (41%) described AWP. Of the 43 patients with AWP, 20 were male and 23 were female. There was no association of AWP with genotype, atopy or concomitant drug intake. CONCLUSION: AWP appears to have an equal sex incidence, and the high number of cases in the population studied would suggest that this condition is underreported.


Asunto(s)
Fibrosis Quística/epidemiología , Envejecimiento de la Piel , Agua/efectos adversos , Adolescente , Adulto , Fibrosis Quística/tratamiento farmacológico , Fibrosis Quística/genética , Regulador de Conductancia de Transmembrana de Fibrosis Quística/genética , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Irlanda del Norte/epidemiología , Tobramicina/efectos adversos , Tobramicina/uso terapéutico , Resultado del Tratamiento , Adulto Joven
6.
Br J Dermatol ; 159(6): 1245-66, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18945319

RESUMEN

Multicentre randomized controlled studies now demonstrate high efficacy of topical photodynamic therapy (PDT) for actinic keratoses, Bowen's disease (BD) and superficial basal cell carcinoma (BCC), and efficacy in thin nodular BCC, while confirming the superiority of cosmetic outcome over standard therapies. Long-term follow-up studies are also now available, indicating that PDT has recurrence rates equivalent to other standard therapies in BD and superficial BCC, but with lower sustained efficacy than surgery in nodular BCC. In contrast, current evidence does not support the use of topical PDT for squamous cell carcinoma. PDT can reduce the number of new lesions developing in patients at high risk of skin cancer and may have a role as a preventive therapy. Case reports and small series attest to the potential of PDT in a wide range of inflammatory/infective dermatoses, although recent studies indicate insufficient evidence to support its use in psoriasis. There is an accumulating evidence base for the use of PDT in acne, while detailed study of an optimized protocol is still required. In addition to high-quality treatment site cosmesis, several studies observe improvements in aspects of photoageing. Management of treatment-related pain/discomfort is a challenge in a minority of patients, and the modality is otherwise well tolerated. Long-term studies provide reassurance over the safety of repeated use of PDT.


Asunto(s)
Carcinoma Basocelular/tratamiento farmacológico , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/uso terapéutico , Guías de Práctica Clínica como Asunto , Enfermedades de la Piel/tratamiento farmacológico , Administración Tópica , Humanos , Fotoquimioterapia/efectos adversos , Fármacos Fotosensibilizantes/efectos adversos
7.
Clin Exp Dermatol ; 33(2): 148-50, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18076688

RESUMEN

An 8-year-old boy presented with eczematous skin lesions, recurrent otitis media and unexplained pyrexias. X-linked agammaglobulinaemia was diagnosed and treatment commenced with intravenous immunoglobulin replacement therapy. X-linked agammaglobulinaemia (XLA) is a primary immunodeficiency syndrome associated with a deficiency of B lymphocytes, caused by a defect in the expression of Bruton's tyrosine kinase. It affects only boys and usually presents before the age of 2 years with recurrent bacterial sinopulmonary infections. IgG levels are usually <2 g/L (normal range 5.4-16.1) and IgM and IgA are usually undetectable. The commonest cutaneous features of XLA are pyogenic skin infections; however, eczema can occur with increased frequency. We report a child who presented with multiple discrete eczematous lesions who subsequently developed eczematous exacerbations several days after administration of intravenous immunoglobulin (IVIg) replacement therapy.


Asunto(s)
Agammaglobulinemia , Enfermedades Genéticas Ligadas al Cromosoma X , Agammaglobulinemia/diagnóstico , Agammaglobulinemia/tratamiento farmacológico , Agammaglobulinemia/inmunología , Anemia/complicaciones , Anemia/terapia , Linfocitos B/inmunología , Niño , Relación Dosis-Respuesta Inmunológica , Eccema/complicaciones , Eccema/tratamiento farmacológico , Enfermedades Genéticas Ligadas al Cromosoma X/diagnóstico , Enfermedades Genéticas Ligadas al Cromosoma X/tratamiento farmacológico , Enfermedades Genéticas Ligadas al Cromosoma X/inmunología , Humanos , Inmunoglobulinas Intravenosas/administración & dosificación , Inmunoglobulinas Intravenosas/efectos adversos , Factores Inmunológicos/administración & dosificación , Factores Inmunológicos/efectos adversos , Masculino , Factores Sexuales , Resultado del Tratamiento
9.
Br J Dermatol ; 154(3): 450-2, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16445774

RESUMEN

BACKGROUND: Glomuvenous malformations (GVMs) are rare bluish lesions that can affect the skin and mucosal surfaces. They represent defects in vasculogenesis. Lesions can occur sporadically or in an autosomal dominant mode of inheritance. Recent studies have shown that mutations in the glomulin gene (GLMN) on chromosome 1p21-22 are responsible for familial GVMs. OBJECTIVES: To search for mutations in GLMN in Irish families with GVMs. METHODS: We identified four Irish families with GVMs and confirmed linkage to chromosome 1p21-22 in these cases. We sequenced the glomulin gene in all affected and unaffected members of the families. Results Linkage analysis showed that affected individuals from the families shared a common haplotype. Mutation analysis revealed a delAAGAA mutation in exon 3 of the glomulin gene in all four families with GVMs. CONCLUSIONS: We confirm that mutations in the glomulin gene are responsible for GVMs and suggest a founder Irish mutation in the glomulin gene in four Irish families.


Asunto(s)
Eliminación de Gen , Tumor Glómico/genética , Síndromes Neoplásicos Hereditarios/genética , Enfermedades Cutáneas Genéticas/genética , Neoplasias Cutáneas/genética , Proteínas Adaptadoras Transductoras de Señales/genética , Secuencia de Bases , Cromosomas Humanos Par 1/genética , Análisis Mutacional de ADN , Femenino , Efecto Fundador , Tumor Glómico/patología , Humanos , Masculino , Síndromes Neoplásicos Hereditarios/patología , Linaje , Enfermedades Cutáneas Genéticas/patología , Neoplasias Cutáneas/patología
10.
Br J Dermatol ; 154(1): 7-20, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16403088

RESUMEN

Photopheresis or extracorporeal photochemotherapy (ECP) is a novel immunomodulatory therapy which involves separation of the patient's leucocyte-rich plasma, followed by ex vivo administration of a photosensitizer and ultraviolet A radiation, before reinfusion. ECP has been used successfully for the treatment of cutaneous T-cell lymphoma (CTCL: Sézary syndrome), graft-versus-host disease (GVHD) and cardiac transplant rejection. ECP has a dose-sparing effect on concurrent immunosuppressive therapy. The procedure induces apoptosis of the irradiated lymphocytes, but the exact mechanism by which ECP exerts its therapeutic effect in these different conditions is uncertain. The treatment has very few adverse effects and in particular is not associated with an increased incidence of opportunistic infections. The evidence for the efficacy of ECP has been appraised by a combined British Photodermatology Group and U.K. Skin Lymphoma Group workshop on the basis of evidence published up to the end of 2001 and on the consensus of best practice. There is fair evidence for the use of ECP in erythrodermic CTCL and steroid-refractory GVHD, but randomized controlled studies are needed. There is good evidence supporting the use of ECP in preventing cardiac rejection following transplantation. Randomized controlled trials have also shown a therapeutic benefit in type 1 diabetes mellitus, but the inconvenience associated with the procedure outweighed the clinical benefit. There is fair evidence not to use ECP for the treatment of systemic sclerosis and multiple sclerosis, and good evidence not to use ECP for other forms of CTCL.


Asunto(s)
Linfoma Cutáneo de Células T/tratamiento farmacológico , Fotoféresis/métodos , Neoplasias Cutáneas/tratamiento farmacológico , Terapia Combinada , Medicina Basada en la Evidencia , Rechazo de Injerto/tratamiento farmacológico , Enfermedad Injerto contra Huésped/tratamiento farmacológico , Trasplante de Corazón , Humanos , Fotoféresis/efectos adversos
11.
Photodermatol Photoimmunol Photomed ; 22(1): 12-7, 2006 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-16436176

RESUMEN

BACKGROUND: Psoriasis is a genetically determined inflammatory skin disease. It is now recognized that narrow band TL-01 phototherapy is an effective treatment for psoriasis. However, ultraviolet (UV) exposure induces p53 mutations in keratinocytes and repeated exposure of skin to UV radiation results in clonal expansion of these initiated p53-mutant cells within the epidermis. AIM: The present study aims to examine epidermal p53 expression in the skin of psoriatic patients at different time points following TL-01 phototherapy. METHODS: Skin samples from patients suffering from plaque-type psoriasis, collected before, during and at the final stages of TL-01 phototherapy were examined for p53 expression by immunohistochemistry. RESULTS/CONCLUSION: Our results showed an increase in p53 expressing keratinocytes following TL-01 phototherapy. Some of these cells were arranged spatially, as conical clones arising from putative stem cell compartments, suggesting that the chronic TL-01 treatment might have triggered cell growth and clonal expansion, an important step in initiating skin carcinogenesis.


Asunto(s)
Queratinocitos/efectos de la radiación , Psoriasis/radioterapia , Proteína p53 Supresora de Tumor/efectos de la radiación , Terapia Ultravioleta/métodos , Adulto , Biopsia , Femenino , Humanos , Inmunohistoquímica , Queratinocitos/citología , Masculino , Persona de Mediana Edad , Psoriasis/patología , Proteína p53 Supresora de Tumor/metabolismo
12.
Curr Pharm Des ; 11(31): 4011-27, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16378507

RESUMEN

The sinusoid anatomy of the penis is complex and requires complicated interaction between smooth muscle and endothelium in order to maintain homeostasis in the adult. The morphogen, Sonic hedgehog (Shh), is a crucial regulator of these processes, along with its down stream targets patched (Ptc), Hox, bone morphogenetic proteins (BMP's), vascular endothelial growth factor (VEGF) and nitric oxide synthase (NOS). Shh is critical for patterning and establishing tissue identity of the penis during embryonic development, is a crucial regulator of penile postnatal differentiation of the sinusoid morphology of the corpora cavernosa, and plays a fundamental role in maintaining sinusoidal structures pertinent to erectile function in the adult rat. Shh and its targets are active in human penes, and decreased in human diabetic penes in parallel with observations in the rat, thus lending clinical significance to the role of abnormal Shh signaling in erectile dysfunction (ED). Application of exogenous Shh protein to rat corpora cavernosa, induces VEGF and NOS proteins, suggesting a potential mechanism through which decreased Shh protein can cause ED. The studies outlined in this review provide in depth analysis of the Shh pathway and signal transduction, its role in penile development, how Shh signaling is altered in a rat model of ED and neuropathy, how abnormal Shh signaling can cause ED, and the clinical significance of the Shh pathway to human ED. These studies will provide valuable insight, at the molecular level, into understanding the mechanisms that under lie ED and lead to new treatment strategies for diabetic impotence.


Asunto(s)
Disfunción Eréctil/fisiopatología , Pene/fisiología , Transducción de Señal , Transactivadores/fisiología , Animales , Disfunción Eréctil/epidemiología , Proteínas Hedgehog , Humanos , Masculino , Pene/anatomía & histología , Pene/fisiopatología , Transactivadores/metabolismo
14.
Photodermatol Photoimmunol Photomed ; 20(6): 289-96, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15533236

RESUMEN

Photochemotherapy (psoralen/UVA (PUVA)) is an efficient therapeutic tool for a wide range of skin diseases. Concern, however, exists regarding the long-term carcinogenic effects of this treatment modality and, as a consequence, is being used less frequently. PUVA remains an important treatment in our therapeutic armamentarium but must be used with caution in those patients with risk factors and cumulative dose exposure must be limited. PUVA-induced cancers show features in common with skin cancers induced by immunosuppressed organ transplant recipients. Tumours in the latter group of individuals are, however, much more aggressive and difficult to manage.


Asunto(s)
Ficusina/efectos adversos , Inmunosupresores/efectos adversos , Trasplante de Órganos , Terapia PUVA/efectos adversos , Fármacos Fotosensibilizantes/efectos adversos , Neoplasias Cutáneas/etiología , Humanos , Enfermedad Iatrogénica , Huésped Inmunocomprometido
16.
Br J Dermatol ; 149(1): 146-50, 2003 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12890208

RESUMEN

BACKGROUND: Previous studies have demonstrated the ultraviolet (UV)-sparing effect of combining topical calcipotriol with broadband UVB in the treatment of psoriasis. OBJECTIVES: To determine if the combination of narrowband TL01 UVB phototherapy and topical calcipotriol produces the same UVB-sparing effect. METHODS: This was a randomized, placebo-controlled, blinded clinical trial. Fifty psoriasis patients were recruited, 25 of whom were randomized into the active group who received TL01 phototherapy together with twice-daily application of calcipotriol cream 50 microg g(-1). The control group received TL01 phototherapy and twice-daily application of a topical emollient as placebo. TL01 phototherapy was given three times per week starting at 70% minimal erythema dose with 20% increments as tolerated for up to approximately 20 sessions. Patients were assessed using the Psoriasis Area and Severity Index (PASI) and Psoriasis Disability Index (PDI). They were evaluated at treatment sessions 8, 14 and 20, and followed up at 5 and 10 weeks post-treatment. Statistical analysis was performed using a two-tailed t-test. RESULTS: There were no significant differences in demographic characteristics and baseline PASI and PDI scores between the two groups. The mean PASI score declined significantly (P < 0.01) for both groups after treatment. The difference in mean PASI score reduction from baseline between the two groups was only significant during the first eight sessions, with a net reduction of 3.6 (95% confidence interval 1.0-6.2, P = 0.008) in the active group relative to the control group. The mean PDI score declined significantly (P < 0.05) for both groups, but there was no statistical difference in mean PDI score reduction between the two groups (P = 0.8) at the end of treatment. The mean cumulative UVB dose for the active group was significantly lower (P < 0.02) at 16 204 mJ cm-2 compared with 21 082 mJ cm-2 for the control group. CONCLUSIONS: We conclude that combining TL01 phototherapy with topical calcipotriol cream has a UVB-sparing effect.


Asunto(s)
Calcitriol/análogos & derivados , Calcitriol/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Psoriasis/tratamiento farmacológico , Terapia Ultravioleta , Adulto , Calcitriol/efectos adversos , Terapia Combinada , Fármacos Dermatológicos/efectos adversos , Método Doble Ciego , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Psoriasis/patología , Psoriasis/radioterapia , Dosis de Radiación , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Terapia Ultravioleta/efectos adversos
17.
Neuroscience ; 114(4): 945-60, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12379250

RESUMEN

The thoracolumbar and lumbosacral spinal cord contain respectively sympathetic and parasympathetic preganglionic neurons that supply the organs of the pelvis including the penis. These neurons are influenced by supraspinal information and receive aminergic projections from the brainstem. The presence of the alpha(1)- and alpha(2)-adrenoceptor subtypes has been demonstrated in the rat spinal cord. In this species, we looked for the presence of alpha(2a)- and alpha(2c)-adrenoceptor subtypes in the sympathetic and parasympathetic preganglionic neurons controlling erection. In adult male rats, transsynaptic axonal transport of pseudorabies virus injected into the penis was combined with immunohistochemistry against alpha(2a)- and alpha(2c)-adrenoceptor subtypes. At 4 days survival time, neurons infected with the pseudorabies virus were solely found in the intermediolateral cell column and dorsal gray commissure of segment T12-L2 and in the intermediolateral cell column of segment L6-S1. Neurons and fibers immunoreactive for alpha(2a)- and alpha(2c)-adrenoceptor subtypes were mainly present in the intermediolateral cell column, the dorsal gray commissure and the ventral horn of the T12-L2 and L5-S1 spinal cord, the dorsal horn displayed only immunoreactive fibers. Pseudorabies virus-infected neurons in the autonomic nuclei were both immunoreactive for alpha(2a)- and alpha(2c)-adrenoceptor subtypes and closely apposed by alpha(2a)- and alpha(2c)-immunoreactive fibers. The results suggest an intraspinal modulation of the noradrenergic and adrenergic control of the autonomic outflow to the penis by pre- and postsynaptic alpha(2) adrenoceptors.


Asunto(s)
Erección Peniana/fisiología , Pene/inervación , Receptores Adrenérgicos alfa 2/fisiología , Médula Espinal/fisiología , Animales , Especificidad de Anticuerpos , Fibras Autónomas Preganglionares/química , Fibras Autónomas Preganglionares/fisiología , Ganglios Parasimpáticos/química , Ganglios Parasimpáticos/citología , Ganglios Parasimpáticos/fisiología , Ganglios Simpáticos/química , Ganglios Simpáticos/citología , Ganglios Simpáticos/fisiología , Herpesvirus Suido 1 , Inmunohistoquímica , Masculino , Neuronas/citología , Neuronas/fisiología , Neuronas/virología , Pene/fisiología , Ratas , Ratas Sprague-Dawley , Receptores Adrenérgicos alfa 2/análisis , Receptores Adrenérgicos alfa 2/inmunología , Médula Espinal/química , Médula Espinal/citología , Transmisión Sináptica/fisiología
19.
J Spinal Cord Med ; 24(3): 148-54, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11585233

RESUMEN

BACKGROUND: Neurological injury results in devastating sexual deficits in both men and women. Effective treatment requires an understanding of the central nervous system (CNS) pathways and physiology. This article emphasizes the essential similarities in the pathways and physiology of sexual function in men and women. METHODS: Literature review. FINDINGS: Systems within the spinal cord are fully capable of generating a large number of sexual responses. Spinal sexual centers may be activated by genital afferents or by descending commands from higher CNS sites. Normal functioning probably involves activation of spinal centers by both descending pathways and afferent stimulation. Afferent stimulation also modulates the activity of supraspinal sites, creating a positive feedback system. Descending control consists of powerful inhibitory and excitatory pathways. An important serotonergic inhibitory pathway has been demonstrated. The medial preoptic region participates in the integration of hormonal and sensory cues necessary for sexual behavior. The medial amygdala and paraventricular nucleus of the hypothalamus also play essential excitatory roles. The paraventricular nucleus projects directly to relevant spinal sites, indicating another important pathway for excitatory control. CONCLUSIONS: Recent advances have markedly enhanced our understanding of the physiology, pharmacology, molecular biology and pathology of sexual mechanisms. This knowledge base is essential in order to understand changes in sexual mechanisms that follow spinal cord injury, and for the development of effective interventions to maximize sexual function in men and women with spinal cord injury.


Asunto(s)
Coito/fisiología , Genitales/inervación , Genitales/fisiopatología , Vías Nerviosas/fisiopatología , Disfunciones Sexuales Fisiológicas/fisiopatología , Traumatismos de la Médula Espinal/fisiopatología , Animales , Femenino , Humanos , Masculino , Disfunciones Sexuales Fisiológicas/etiología , Traumatismos de la Médula Espinal/complicaciones
20.
J Urol ; 166(2): 746-55, 2001 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-11458128

RESUMEN

PURPOSE: Erectile dysfunction is a common pathological development in individuals with diabetes mellitus. Nitric oxide synthase (NOS) is essential for regulation of normal penile erection and NOS protein activity has been shown to be altered with diabetes. Several different isoforms and subtypes of NOS exist. However, little is known about how the distribution and abundance of these isoforms are altered with diabetes. We characterized the distribution and abundance of NOS isoforms and explored how they are altered with diabetes and result in erectile failure. MATERIALS AND METHODS: In situ hybridization and quantitative reverse transcriptase-polymerase chain reaction were done to measure the abundance and distribution of NOS-Ia, NOS-Ib, NOS-Ic, NOS-II and NOS-III in control and diabetic (BB/WOR) rats. Protein was localized by immunohistochemical analysis and alterations in protein abundance with diabetes were examined by Western blot analysis. RESULTS: NOS-I, NOS-II and NOS-III were observed in the endothelium lining the cavernous spaces and in the epithelium of the urethra. NOS-I protein was also present in the nerves of control and diabetic penes. We observed an increase in NOS-II expression around the dorsal nerves of diabetic penes, a decrease in NOS-III expression in diabetic pelvic ganglia and a decrease in NOS-Ib expression in the diabetic penis. NOS-I protein abundance was significantly decreased in diabetic pelvic ganglia. CONCLUSIONS: To our knowledge this is the first report of regional differences in the distribution of NOS-III in the urethra and altered NOS-Ib gene expression with diabetes.


Asunto(s)
Diabetes Mellitus Experimental/enzimología , Óxido Nítrico Sintasa/análisis , Animales , Western Blotting , Epitelio/enzimología , Inmunohistoquímica , Masculino , Óxido Nítrico Sintasa de Tipo I , Óxido Nítrico Sintasa de Tipo II , Óxido Nítrico Sintasa de Tipo III , Pene/enzimología , Ratas , Distribución Tisular , Uretra/enzimología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...